life.
science.
discovery.

MBL International provides high-quality products and solutions to advance life science research and clinical diagnostics.

Learn More

Product Highlight

MHC Tetramers

 

MHC Tetramers and Monomers for high specificity immune monitoring.

Patented α3 mutation for reduced background.

Learn More

Product Highlight

TransFix®: A Cellular Antigen Stabilization Reagent

 

TransFix® is a versatile cellular antigen stabilization solution that prevents cellular degradation in a variety of specimen types for flow cytometric analysis.

Learn More

Product Highlight

Immuno-Oncology Solutions

MBL International offers Antibodies, MHC Tetramers and Monomers to study immune checkpoint and other cancer research targets.

 

Learn More

Product Highlight

IL-18 (Interleukin 18)

 

MBL International’s IL-18 products are highly cited and widely trusted.

Discover how MBL International can help your IL-18 research.

Learn More
  • Spotlight
  • Promotions
  • Partner
  • News + Events
  • New Products
  • Blog

TransFix/EDTA Vacuum Blood Collection Tubes (TVTs)

TVTs are now available in a convenient 2-tube pack presentation for in vitro diagnostic (IVD) use in the USA.

TransFix/EDTA Vacuum Blood Collection Tubes (TVTs) are intended for collection and storage of human whole blood specimens for immunophenotyping of white blood cells by flow cytometry.

Now, IVD TransFix/EDTA Vacuum Blood Collection Tubes are available in a convenient 2-tube pack presentation, as well as 50-tube packs.

Learn more about this TransFix product.

 

 

 

COLLABORATE WITH MBLI

Partnering with pharmaceutical, biotechnology, and diagnostics companies to out-license our innovative technologies and products supporting life science research, develop companion diagnostics and in-license IVD technologies/products in the areas of cancer, autoimmune diseases, infectious diseases, allergy and cytological/pathological testing.

MBL International will be attending:

READ MORE

Press Release

JSR’s Life Sciences Division Appoints New CEO for MBL International

 

Jan. 23, 2018 – Sunnyvale, CA – JSR Life Sciences, the life sciences-focused business unit of JSR Corporation, announced today that it has appointed Dr. Nalini Murdter as the President and Chief Executive Officer of MBL International (MBLI) effective immediately.

Read More

May 22nd, 2017: MEDICAL & BIOLOGICAL LABORATORIES Co., Ltd. (MBL) announced that it has entered into a collaboration agreement with the p53 Laboratory, Agency for Science, Technology and Research (A*STAR) in Singapore to establish the novel screening technology which accelerates the drug discovery targeting Protein-Protein Interactions (PPIs).

February 28th, 2017: MEDICAL & BIOLOGICAL LABORATORIES Co., Ltd. concludes a patent licensing agreement with the University of Toyama concerning a rapid antibody production technique

 

 

  • ELISA Kits and Antibodies – 2 new ELISA kits and new antibodies, along with 134 trial size antibodies now available
  • Fluoppi Protein-Protein Interaction – Visualize and Screen PPI’s with 18 new pre-made vector sets of popular oncology targets
  • Next-Generation Nano Culture Plates – 3D Cell Culture plates for tumor modeling and other applications, easy to use with improved imaging
  • TransFix® – A patented stabilization solution that is easy to use and preserves cells and cellular antigens for up to 14 days prior to analysis

  • Learn why IL-18 is an exciting biomarker for various diseases

    Tue, 31 Jul 2018 17:00:00 GMTBy: nakajo.tomohiro@mbl.co.jp (Tomohiro Nakajo)

    As described in previous blog posts, our IL-18 related products are used widely among researchers around the world. IL-18 plays an important role in the cytokine network. Abnormal values of IL-18 are seen in various disease areas such as allergy or autoimmune diseases. 
    In this blog, we discuss two diseases correlated with IL-18. Neither of them are allergy or autoimmune diseases, but very interesting nonetheless.
    •Acute kidney injury (AKI)
    Urine IL-18 levels become higher in AKI. This was first reported by the research group comprised of Yale University, University of Colorado, and Harvard Medical School in 20051. Before this, serum creatinine was used routinely to diagnose AKI.  However, because several days are required to detect changes in creatinine, there were many cases of missed therapeutic intervention. Also creatinine measurements can be nonspecific as they can occur as a result of several non-renal factors. This research group measured IL-18 levels in urine samples using MBL International’s human IL-18 ELISA kit (7620) and reported that IL-18 levels were significantly different at 24 and 48 hours before AKI in patients with the disease as compared with control patients. Currently, many researchers continue to evaluate IL-18 as one of the diagnostic biomarker possibilities for AKI. (PMID: 16148039).
    •Multiple myeloma (MM)
    It is known that serum IL-18 levels become higher in MM patients. Recently, these mechanisms were reported by an Australian research group.2 They reported that MM niche cells-derived IL-18 accelerate generation of myeloid-derived suppressor cells (MDSCs), followed by the proliferated MDSCs inhibiting T cells to attack MM cells, and finally MM cells proliferate and disease progression is accelerated. In this report, high levels of bone marrow plasma IL-18 are associated with poor overall survival in MM patients. Furthermore, they report that anti-IL-18 antibody has the possibility of becoming a treatment for those patients. (PMID: 29551594). It is very interesting to learn that IL-18 inhibits T cells to attack MM cells indirectly. Future research is sure to have even more exciting discoveries!
    There are many other diseases where IL-18 is found to have a critical role or function. MBL International is eagerly looking forward to the progress of future IL-18 biomarker research as a provider of high quality IL-18 ELISA kits and associated products.
    References

    Parikh CR. et al., Urine IL-18 Is an Early Diagnostic Marker for Acute Kidney Injury and Predicts Mortality in the Intensive Care Unit. J. Am. Soc. Nephrol., 16, 3046-52 (2005), PMID: 16148039
    Nakamura K. et al., Dysregulated IL-18 Is a Key Driver of Immunosuppression and a Possible Therapeutic Target in the Multiple Myeloma Microenvironment. Cancer Cell, 33, 634-48 (2018), PMID: 29551594 Read more

  • Improve your neutralization using monoclonal IL-18 antibodies

    Tue, 19 Jun 2018 17:00:00 GMTBy: nakajo.tomohiro@mbl.co.jp (Tomohiro Nakajo)

    Interleukin-18 (IL-18) is a member of the IL-1 superfamily and synthesized as an inactive precursor that requires processing by caspase-1 to become an active cytokine. IL-18 plays a major role in the production of interferon-γ (IFN-γ) from T cells and natural killer cells. Refresh your memory by reviewing a couple of previous blog posts. Read more
  • Tips for successful results using our extremely popular IL-18 ELISA kits

    Wed, 30 May 2018 17:00:00 GMTBy: nakajo.tomohiro@mbl.co.jp (Tomohiro Nakajo)

    Interleukin-18 (IL-18) is a member of the IL-1 superfamily and synthesized as an inactive precursor requiring processing by caspase-1 into an active cytokine. IL-18 plays a major role in the production of interferon-γ (IFNγ) from T cells and natural killer cells. Refresh your memory by reviewing a couple of previous blog posts. Read more

View All